A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
NCT07098338
This study is recruiting at 3 US sites in 3 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a Phase II, multi-center, open-label platform study evaluating novel combination treatment options in participants with locally advanced or metastatic NSCLC. The study will consist of several sub-studies, each evaluating the safety, tolerability, and preliminary antitumour activity of various treatment combinations. This study will be conducted in approximately 80 centers globally across 10 countries.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Non-Small Cell Lung Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- AstraZeneca
- Last updated on ClinicalTrials.gov
- October 15, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Research Site · Santa Monica, CA
Georgia · 1
- Research Site · Atlanta, GA
Virginia · 1
- Research Site · Fairfax, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.